Trials / Completed
CompletedNCT00877032
Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration
A Phase I, Double-masked, Placebo-controlled Study Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Immunogenicity Of Single Escalating Doses Of Rn6g In Patients With Dry, Age-related Macular Degeneration (Amd)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 57 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of RN6G in patients with dry, age-related macular degeneration.
Conditions
- Age-Related Maculopathy
- Age-Related Maculopathies
- Eye Diseases
- Retinal Degeneration
- Macular Degeneration
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | RN6G | intravenous, single dose, dose ranging from 0.3mg/kg up to a maximum of 40 mg/kg. |
| BIOLOGICAL | Placebo | intravenous, single dose with experimental dose. |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2011-07-01
- Completion
- 2011-07-01
- First posted
- 2009-04-07
- Last updated
- 2015-03-31
- Results posted
- 2015-03-31
Locations
20 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00877032. Inclusion in this directory is not an endorsement.